Navigation Links
Getting a cancer drug to patients takes both scientific and business smarts
Date:1/23/2014

What if an experimental treatment for an aggressive breast cancer had the potential to save women's lives, but nobody could use it because there was no money to develop and test it? With funding sources for research and development more scarce than in the past, it is not an unusual situation. It's a problem that Sourav Sinha, a Master's degree candidate at Rutgers' Graduate School of Biomedical Sciences, is working to tackle head-on.

Sinha is leading a team entered in the Breast Cancer Startup Challenge, a worldwide competition sponsored by the Avon Foundation, the Center for Advancing Innovation and the National Cancer Institute. The goal is to take a drug that shows promise in the laboratory a powerful toxin created and patented by scientists at the National Institutes of Health and develop a business plan to guide its development for potential use in patients.

"We have this unique opportunity to get a powerful treatment to breast cancer patients who desperately need it," says Sinha, who grew up in Holmdel, N.J., and aspires to be a physician as well as a research scientist. "I see this as a new, exciting avenue through which my team and I can make a meaningful contribution to health."

Bringing a drug to market is a much more daunting process than people might realize.

This drug is designed to kill individual cells altered by the HER-2-positive gene mutation that is responsible for as many as 25 percent of all breast cancers. "The toxin is in a very early stage of development right now," says Sinha, "but if it works it will be huge."

That is where the need for a business plan comes in. The drug's inventors have shown it kills cancer cells in the lab, but in order for it to work in people, an intricate transport system is also needed to carry the toxin through patients' bodies and deliver it to diseased cells, while bypassing surrounding healthy cells.

Choosing the right mechanism requires an extensive knowledge of biochemistry. But it also demands business sense: to negotiate financial agreements with biotech companies that have expertise to construct the delivery system. Specialized components include synthetic antibodies that are specifically engineered to seek out HER-2-positive cancer cells, as well as "linkers" that would fuse the toxin to the antibodies as a space capsule might be attached to a booster rocket until just the moment when, inside the cell, the toxin detonates.

If the product ultimately works, each of these companies will see a share of what could be substantial profits. Those financial details, and many others, are essential parts of the business plan, and need to be worked out now. Sinha and his team would then take the completed plan to venture capitalists and large foundations which he hopes he and his team can convince to put up the capital needed to fund both the manufacturing process and the all-important human clinical trials that would follow.

Attacking HER-2-positive breast cancer may be just the start. If, as Sinha expects, the toxin can also be combined with different antibodies that seek out other cancers, Sinha says the drug has "nearly endless" cancer fighting potential.

"He is a very impressive young man," says Joseph Bertino, chief scientific officer at the Rutgers Cancer Institute of New Jersey and a professor of medicine and pharmacology at Rutgers Robert Wood Johnson Medical School.

Bertino, whose own research focuses on targeted cancer therapies, is one of several Rutgers faculty members who have advised Sinha. "He has collaborators lined up," Bertino adds, "and I think he has a real shot at it." Sinha and his team have formed a company, OncoLinx LLC, to help advance their plans.

Sinha's foray into the business side of drug development is a sign of rapidly changing times. In the past, nearly all who earned doctorates in the biomedical sciences stayed in academia. But now, Bertino notes, "some of our best scientists are working with biotech companies and big pharma. It's important for them to understand what industry is all about, so we at Rutgers are trying to make sure it's part of their education."


'/>"/>

Contact: Rob Forman
robert.forman@rutgers.edu
973-972-7276
Rutgers University
Source:Eurekalert  

Related medicine news :

1. Study: Women not getting enough exercise; at risk of developing metabolic syndrome
2. HPV vaccine completion rate among girls is poor, getting worse
3. American Kids Getting Fewer Prescription Drugs: Study
4. Getting your message across
5. Cholesterol Levels Getting Better for U.S. Kids: CDC
6. Kids need at least 7 minutes a day of vigorous physical activity, but most arent getting that
7. U.S. Kids Getting Enough Sleep After All: Survey
8. Fitquip: Getting Fit for Christmas on the Beach
9. New Blog Post from iHealthology.com Announces Why Staying Fit Means Getting on the Move
10. Quorn Foods Inc. Releases a Statement Following an Article on Getting the Most Out of a Vegetarian Healthy Food Diet
11. People with diabetes in Ontario getting fewer government-funded eye exams, new study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Getting a cancer drug to patients takes both scientific and business smarts
(Date:5/4/2016)... ... May 04, 2016 , ... Connor Sport Court ... for the 2016 NCAA Men’s National Collegiate Volleyball Championship. , Sport ... championship to be held May 5-7 at Pennsylvania State University’s Rec Hall in ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... families of Camas and Vancouver, WA, has announced the latest beneficiary of ... Breast Cancer Foundation and their Mammography Program, which provides free mammograms and ...
(Date:5/4/2016)... ... May 04, 2016 , ... Level 10 Head Over Heels Athletic ... to the University of Arizona for the fall of 2019. , After a ... Brovedani’s commitment to the GymCats came from her connection with the coaching staff and ...
(Date:5/4/2016)... MA (PRWEB) , ... May 04, 2016 , ... ... help fund Dr. Todd Rider's research and development of DRACO broad-spectrum antiviral therapeutics. ... In the campaign that starts on May 3, 2016 at http://igg.me/at/EndTheVirus ...
(Date:5/4/2016)... ... May 04, 2016 , ... Olshan ... commercial real estate proudly announced that its service-based charitable program, Olshan Outreach, successfully ... portfolio-wide will continue Olshan Properties’ annual philanthropic tradition in 2016 with the ‘Fight ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 2016  Compass Diversified Holdings (NYSE: CODI ... of leading middle market businesses, announced today its consolidated ... 2016. First Quarter 2016 Highlights , ... or "Cash Flow") of $13.6 million for the first ... $15.0 million for the first quarter of 2016; ...
(Date:5/4/2016)... COUNTY, Calif. , May 4, 2016  It,s time for an upgrade. There ... shown on a brilliant 3.5 inch LCD, the illustrious DVMAXX HD  offers unparalleled ... brands as well as a world class manufacturer of innovative technology.  Photo ... ... ...
(Date:5/4/2016)... YORK , May 4, 2016 ... Share, Development, Growth and Demand Forecast to 2022 - Industry ... User (Hospital, Diagnostic Center and Others)" by P&S Market Research, ... $4,894.3 million in 2015, and it is expected to grow ... type, the high slice type segment is expected to witness ...
Breaking Medicine Technology: